More Articles on Orthopedic Devices:
US Soft Tissue Solutions to Grow to $2B
Study: MoM Hip Implants Not Linked to Cancer After 7 Yearsa
InVivo Therapeutics Names Interim Chief Science Officer Featured
Written by Jaimie Oh | September 21, 2012
InVivo Therapeutics Holdings, a developer of technologies for spinal cord injuries and neurotrauma, appointed Brian Hess as interim chief science officer.
Prior to this appointment, Mr. Hess served as InVivo's director of product development, a position he has held since February. Before joining InVivo, he spent eight years at Stryker developing biomaterial technologies for the orthopedic market. At Stryker, he was instrumental in leading multiple product development teams through the FDA process and developing HydroSet.
© Copyright ASC COMMUNICATIONS 2011. Interested in LINKING to or REPRINTING this content? View our policies here.